Skip to content

Innate and Adaptive Immunity

PRRs and TLRs, antibodies, V(D)J diversity, hybridomas, MHC and antigen presentation, T/B activation, complement, hypersensitivity, tolerance and vaccines.

  • 28 min read
  • Updated
On this page · 22 sections
  1. Prerequisites
  2. The Hook: Two Probes, One Fragment
  3. Innate vs Adaptive Immunity
  4. Pattern Recognition Receptors and Toll-like Receptors
  5. Antigens, Immunogens, Haptens and Epitopes
  6. Antibody Structure, Classes and Functions
  7. Generation of Antibody Diversity
  8. Monoclonal Antibodies: the Hybridoma Principle
  9. MHC and Antigen Presentation
  10. T and B Cell Activation
  11. Complement
  12. Hypersensitivity (Gell and Coombs)
  13. Tolerance and Autoimmunity
  14. Immunodeficiency
  15. Vaccines as an Immunological Concept
  16. Memory Tricks
  17. Don’t Confuse
  18. Common Mistakes
  19. Practice
  20. Quick Revision Table
  21. Key Takeaways
  22. What’s Next

Prerequisites

The Hook: Two Probes, One Fragment

How CSIR NET asks it. Part B: which TLR sees which ligand, which Ig class does what, which enzyme makes which kind of diversity, which MHC presents to which T cell, which complement protein forms the C3 convertase, which hypersensitivity type fits an example. Part C: knockout and deficiency phenotypes, complement assay patterns, hybridoma selection logic, MHC-restriction experiments and gene-segment arithmetic.


Innate vs Adaptive Immunity

FeatureInnateAdaptive
ReceptorsGermline-encoded pattern recognition receptors (PRRs), same on every cell of a typeRearranged TCR and BCR, one specificity per clone
RecognisesConserved microbial patterns (PAMPs) and damage signals (DAMPs)Specific epitopes on any molecule
SpeedMinutes to hoursDays (primary); faster on re-exposure
MemoryEssentially none (classically)Yes: memory B and T cells
CellsNeutrophils, macrophages, dendritic cells, NK cells, mast cells, eosinophils, basophils, innate lymphoid cellsT cells, B cells
Soluble factorsComplement, acute-phase proteins, interferons, defensinsAntibodies

The two systems are not separate. Dendritic cells sense pathogens through PRRs and then activate naive T cells; antibodies direct complement and phagocytes to targets.

Barriers and innate effectors

  • Physical and chemical barriers: skin (keratin, low pH, fatty acids), mucus and cilia, stomach acid, lysozyme in tears and saliva (cleaves peptidoglycan), defensins and other antimicrobial peptides, and competition from resident commensal microbes.
  • Phagocytes: neutrophils (first to arrive, short-lived) and macrophages (long-lived, also present antigen). Killing in the phagolysosome uses the NADPH oxidase (respiratory burst), lysosomal enzymes and nitric oxide.
  • Dendritic cells (DCs): the link to adaptive immunity; they capture antigen in tissues and migrate to lymph nodes to present it.
  • NK cells: kill cells that have lost MHC class I (“missing self”) or display stress ligands, using perforin and granzymes; also kill antibody-coated cells by ADCC through FcγRIII (CD16).
  • Mast cells, basophils, eosinophils: granule-rich cells for inflammation, allergy and anti-helminth defence.

Pattern Recognition Receptors and Toll-like Receptors

Drosophila Toll was first known as a dorsoventral patterning gene; flies lacking Toll signalling were found to be highly susceptible to fungal infection. Mammalian homologues, the Toll-like receptors, have an extracellular leucine-rich repeat domain and a cytoplasmic TIR domain.

ReceptorLocationLigand (PAMP)
TLR4 (with MD-2; CD14 helps)Plasma membrane (also signals from endosomes)LPS of Gram-negative bacteria
TLR2 (with TLR1 or TLR6)Plasma membraneLipoproteins and lipopeptides, lipoteichoic acid
TLR5Plasma membraneFlagellin
TLR3EndosomedsRNA
TLR7 / TLR8EndosomessRNA
TLR9EndosomeUnmethylated CpG DNA
NOD1 / NOD2 (NLRs)CytosolPeptidoglycan fragments (NOD2: muramyl dipeptide)
NLRP3 inflammasomeCytosolMany danger signals (K⁺ efflux, crystals, extracellular ATP)
RIG-I, MDA5 (RLRs)CytosolViral RNA (RIG-I: 5′-triphosphate RNA)
cGAS → STINGCytosolCytosolic dsDNA
C-type lectins (Dectin-1, mannose receptor)Plasma membraneβ-glucans, mannose-rich glycans

Nucleic-acid-sensing TLRs sit in endosomes, which keeps them away from the host’s own extracellular DNA and RNA.

flowchart LR
  A["Surface TLRs
TLR1/2/4/5/6"] --> M["MyD88"] B["Endosomal TLR7/8/9"] --> M C["Endosomal TLR3"] --> T["TRIF"] A2["TLR4 (endosome)"] --> T M --> I["IRAK–TRAF6 → IKK"] I --> N["NF-κB → TNF-α, IL-1β, IL-6, IL-12
B7 (CD80/86) up on DCs"] T --> R["IRF3 → type I interferon"] T --> N
  • MyD88 is used by every TLR except TLR3; TLR4 is the one that uses both MyD88 and TRIF.
  • Inflammasome: NLRP3 recruits the adaptor ASC and pro-caspase-1. Active caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms and cleaves gasdermin D, whose pores cause pyroptosis. Two signals are needed: priming (NF-κB makes pro-IL-1β and NLRP3) and activation.
  • Type I interferons (IFN-α, IFN-β) act through JAK–STAT to put neighbouring cells into an antiviral state.

Inflammation

The classic signs are rubor, calor, tumor, dolor (redness, heat, swelling, pain), with loss of function. Mediators: histamine (mast cells; vasodilation, permeability), prostaglandins and leukotrienes (arachidonic acid), bradykinin, complement C3a and C5a, and cytokines TNF-α, IL-1, IL-6. IL-6 drives the liver to make acute-phase proteins (CRP, mannose-binding lectin, fibrinogen).

Leukocytes leave blood in steps: selectin-mediated rolling → chemokine signalling activates integrins (LFA-1, a β2 integrin) → firm adhesion to ICAM-1 → diapedesis between endothelial cells → migration up the chemokine gradient. Integrins and selectins are covered on the adhesion and junctions page.


Antigens, Immunogens, Haptens and Epitopes

TermMeaning
AntigenAny molecule that binds an antibody or a TCR (as peptide–MHC)
ImmunogenA molecule that induces an immune response. Every immunogen is an antigen; not every antigen is an immunogen
HaptenA small molecule that binds antibody but cannot induce a response alone; becomes immunogenic when coupled to a carrier protein (Landsteiner)
Epitope (antigenic determinant)The part of an antigen actually bound
ParatopeThe antigen-binding site on the antibody

B-cell epitopes lie on the accessible surface of native antigen and are often conformational (discontinuous residues brought together by folding). T-cell epitopes are linear peptides produced by processing and bound in an MHC groove, so they can come from anywhere in the protein, including its interior.

Immunogenicity rises with foreignness, size, chemical complexity (proteins > polysaccharides > lipids and nucleic acids alone), the ability to be processed and presented, an appropriate dose and route, and adjuvants. Adjuvants supply innate signals (often PRR ligands) that raise B7 on dendritic cells, which is why they help.


Antibody Structure, Classes and Functions

An IgG molecule has two identical heavy (H) chains and two identical light (L) chains joined by disulphide bonds into a Y. Light chains are κ or λ. Each chain is built from immunoglobulin domains (about 110 residues, a β-sandwich held by an intrachain disulphide).

  • Light chain: V\(_L\) + C\(_L\).
  • Heavy chain: V\(_H\) + C\(_H\)1 + hinge + C\(_H\)2 + C\(_H\)3 (IgG, IgA, IgD). IgM and IgE have no hinge and an extra C\(_H\)4 domain.
  • Each V domain has three hypervariable loops (CDR1–3); the six CDRs of V\(_H\) and V\(_L\) form the paratope. CDR3 is the most variable because it spans the gene-segment junctions.
  • Papain cuts above the hinge disulphides: 2 Fab + 1 Fc. Pepsin cuts below them: one bivalent F(ab′)₂ plus small Fc fragments.
ClassForm in serumKey features and functions
IgGMonomerMost abundant in serum; longest half-life; crosses the placenta (FcRn); opsonisation, ADCC, neutralisation; activates complement (subclass-dependent); main class of the secondary response
IgMPentamer with J chain (monomer on B-cell surface)First antibody of a primary response; best complement activator; high avidity (10 sites)
IgAMonomer in serum; dimer with J chain and secretory component in secretionsMucosal immunity; transcytosed by the polymeric Ig receptor; in milk, tears, saliva
IgEMonomerLowest serum level; binds FcεRI on mast cells and basophils; allergy and anti-helminth defence
IgDMonomerCo-expressed with IgM on naive mature B cells (alternative splicing); little in serum

Serum concentration order: IgG > IgA > IgM > IgD > IgE. On the B-cell surface the immunoglobulin pairs with Igα/Igβ (CD79a/b), whose ITAMs carry the signal. Membrane and secreted forms of one heavy chain come from alternative RNA processing at the 3′ end (see Transcription and RNA Processing).


Generation of Antibody Diversity

V(D)J recombination

Heavy-chain loci contain multiple V, D and J segments; light-chain loci have V and J only. In each developing B cell one segment of each type is joined.

  • RAG1/RAG2 recognise recombination signal sequences (RSS): a conserved heptamer and nonamer separated by a 12 bp or 23 bp spacer.
  • 12/23 rule: joining occurs only between a segment flanked by a 12-bp spacer RSS and one flanked by a 23-bp spacer RSS. In the heavy chain, V and J carry 23-bp RSSs and D carries 12-bp RSSs on both sides, so V cannot join J directly; D must come between.
  • RAG cuts make hairpin coding ends and blunt signal ends. Artemis (with DNA-PKcs) opens the hairpins, often off-centre, adding palindromic P-nucleotides; TdT adds random, non-templated N-nucleotides; exonucleases trim. Ku70/80, XRCC4 and DNA ligase IV (NHEJ) seal the joint.
  • Coding joints are imprecise; signal joints are precise (signal joints in deletional rearrangement form a circle that is lost).

Order in B-cell development: heavy chain D→J then V→DJ (pro-B) → μ chain pairs with the surrogate light chain (λ5 + VpreB) as the pre-BCR (pre-B), which signals proliferation and allelic exclusion → light chain rearranges (κ first, then λ) → immature B with surface IgM.

flowchart LR
  G["Germline
V…D…J…Cμ"] -->|"RAG: D→J"| DJ["DJ joined"] DJ -->|"RAG: V→DJ"| VDJ["VDJ–Cμ
pre-BCR"] VDJ -->|"light chain V→J"| IgM["Surface IgM
(+ IgD by splicing)"] IgM -->|"antigen + Tfh help
AID in germinal centre"| SHM["Somatic hypermutation
→ affinity maturation"] IgM -->|"AID at switch regions
+ cytokines, CD40L"| CSR["Class switch
IgG, IgA, IgE"]

The five sources of diversity

SourceMechanismWhen
Multiple germline segmentsMany V, D, J to choose fromAntigen-independent (bone marrow)
Combinatorial joiningAny V with any (D) JAntigen-independent
Junctional diversityImprecise joining, P- and N-nucleotides (TdT)Antigen-independent
Combinatorial H–L pairingAny heavy with any light chainAntigen-independent
Somatic hypermutation (SHM)Point mutations in rearranged V regions by AIDAntigen-dependent, germinal centres

For a hypothetical species with \(n_V, n_D, n_J\) heavy-chain segments and light-chain sets \(\kappa\) and \(\lambda\):

$$\text{Combinations} = (n_V n_D n_J)_H \times \left[(n_V n_J)_\kappa + (n_V n_J)_\lambda\right]$$

Junctional diversity and SHM multiply this further, which is why the real repertoire is far larger than the combinatorial number.

Somatic hypermutation and affinity maturation

In germinal centres, activation-induced cytidine deaminase (AID) deaminates C to U in rearranged V regions. Repair of these lesions introduces point mutations at a rate far above the background. B cells whose mutated BCR binds antigen (displayed on follicular dendritic cells) better win help from T follicular helper (Tfh) cells and survive: affinity maturation. This is why antibody affinity rises over the course of a response and after boosting.

Class switch recombination (CSR)

AID also acts at repetitive switch (S) regions upstream of each C\(_H\) gene (except Cδ). Recombination between Sμ and a downstream S region deletes the intervening constant genes. The VDJ is unchanged, so specificity is kept; only the effector function changes. CSR needs CD40–CD40L contact with a T cell and is directed by cytokines (mouse examples: IL-4 → IgG1 and IgE; IFN-γ → IgG2a; TGF-β → IgA). IgM to IgD is not switching; it is alternative splicing.


Monoclonal Antibodies: the Hybridoma Principle

Köhler and Milstein (1975) solved a mismatch: B cells make a single specificity but die in culture; myeloma cells are immortal but make an irrelevant (or no) antibody. Fusing the two gives a hybridoma, an immortal cell secreting one antibody.

The selection logic:

  1. Spleen B cells from an immunised mouse are fused with a myeloma line that lacks HGPRT and secretes no antibody of its own (polyethylene glycol is the usual fusogen).
  2. Cells are grown in HAT medium: aminopterin blocks dihydrofolate reductase and therefore de novo purine and thymidylate synthesis. Cells survive only through the salvage pathway, which needs HGPRT (to use hypoxanthine) and thymidine kinase (to use thymidine).
  3. Unfused myeloma cells die (no HGPRT). Unfused B cells die (finite lifespan). Hybrids survive: HGPRT from the B cell, immortality from the myeloma.
  4. Wells are screened (for example by ELISA) for the wanted specificity and cloned by limiting dilution, so each line descends from one cell.

Mouse antibodies are themselves immunogenic in humans, so therapeutic antibodies are made chimeric (mouse V, human C), humanised (only mouse CDRs grafted into a human framework) or fully human.


MHC and Antigen Presentation

T cells see antigen only as peptide bound to an MHC molecule on another cell: MHC restriction (Zinkernagel and Doherty). Human MHC = HLA, on chromosome 6: class I HLA-A, -B, -C; class II HLA-DP, -DQ, -DR; class III genes include complement C2, C4, factor B and TNF. Mouse MHC = H-2 (chromosome 17). MHC genes are highly polymorphic and codominantly expressed.

FeatureMHC class IMHC class II
Chainsα chain (α1, α2, α3) + β₂-microglobulin (not MHC-encoded)α chain + β chain (each two domains)
Groove formed byα1 + α2α1 + β1
Groove endsClosedOpen
Peptide length8–10 residues (usually 9)Longer (about 13–25); ends overhang
Expressed onAll nucleated cellsProfessional APCs: DCs, macrophages, B cells; thymic epithelium
Peptide sourceCytosolic (endogenous) proteinsEndocytosed (exogenous) proteins
Presents toCD8 T cells (CD8 binds α3)CD4 T cells (CD4 binds β2)

The two pathways

flowchart TB
  subgraph I["Class I: cytosolic pathway"]
    P1["Cytosolic protein"] --> PR["Proteasome
(immunoproteasome after IFN-γ)"] PR --> TAP["TAP1/TAP2 pumps peptide into ER"] TAP --> PLC["Peptide-loading complex:
tapasin, calreticulin, ERp57; ERAP trims"] PLC --> S1["Class I–peptide to surface → CD8 T cell"] end subgraph II["Class II: endocytic pathway"] E1["Endocytosed protein"] --> EN["Endosome/lysosome proteases"] ER2["Class II + invariant chain (Ii) in ER"] --> MIIC["Ii degraded → CLIP left in groove"] EN --> DM["HLA-DM swaps CLIP for peptide"] MIIC --> DM DM --> S2["Class II–peptide to surface → CD4 T cell"] end
  • Invariant chain (Ii, CD74) blocks the class II groove in the ER and targets class II to endosomes. CLIP is the Ii fragment left in the groove; HLA-DM (a non-classical class II molecule) catalyses its exchange for peptide.
  • Without TAP or β₂-microglobulin, class I is unstable and little reaches the surface; such mice and patients have very few CD8 T cells.

Cross-presentation

Some dendritic cells (the cDC1 subset; CD8α⁺ DCs in mouse spleen) load exogenous antigen onto class I. This lets naive CD8 T cells be primed against antigens made only in other cells (for example tumour cells, or cells infected by viruses that do not infect DCs). Routes include escape of phagocytosed protein into the cytosol for proteasomal processing and TAP transport, and loading within the phagosome.


T and B Cell Activation

T cells: three signals

SignalMoleculesOutcome
1. AntigenTCR + CD4/CD8 binds peptide–MHC; Lck phosphorylates CD3/ζ ITAMs; ZAP-70 → LAT, SLP-76 → PLCγ1IP₃ → Ca²⁺ → calcineurin → NFAT; DAG → PKCθ → NF-κB; Ras → MAPK → AP-1
2. Co-stimulationCD28 on T cell binds B7-1 (CD80) / B7-2 (CD86) on an activated APCIL-2 and CD25 (IL-2Rα) induced; survival, proliferation
3. CytokinesPolarising cytokines from the APC and environmentChoice of effector fate

Signal 1 without signal 2 → anergy. Since B7 is induced on DCs by PRR signalling, the innate system decides when adaptive responses start. CTLA-4 binds B7 with higher affinity than CD28 and inhibits; PD-1 (ligands PD-L1/PD-L2) also inhibits. Blocking these “checkpoints” with antibodies releases anti-tumour T cells. Cyclosporin A and tacrolimus inhibit calcineurin; rapamycin inhibits mTOR downstream of the IL-2 receptor.

CD4 subsetInduced byMaster regulatorSignature outputMain job
Th1IL-12, IFN-γT-betIFN-γMacrophage activation, intracellular microbes
Th2IL-4GATA3IL-4, IL-5, IL-13Helminths, IgE, allergy
Th17TGF-β + IL-6 (IL-23 sustains)RORγtIL-17, IL-22Extracellular bacteria and fungi; neutrophils
TfhIL-6, IL-21Bcl-6IL-21, CD40LB-cell help in germinal centres
Treg (induced)TGF-β + IL-2FoxP3IL-10, TGF-βSuppression, tolerance

CD8 cytotoxic T cells kill targets by perforin and granzymes and by Fas ligand, both of which trigger apoptosis.

B cells: T-dependent vs T-independent

The BCR signals through Igα/Igβ (Syk, Btk, PLCγ2). The co-receptor CD21 (CR2)–CD19–CD81 binds complement fragment C3d on the antigen and lowers the activation threshold, another link from innate to adaptive.

T-dependent (TD)T-independent (TI)
AntigenProteinsTI-1: polyclonal activators such as LPS (at high dose). TI-2: repetitive polysaccharides that crosslink many BCRs
HelpB cell presents antigen peptide on class II to a Tfh cell primed by the same antigen; CD40L–CD40 + cytokinesNone (TI-2 may get some help from cytokines)
Germinal centreYesLittle or none
Class switching and SHMYesLimited; mostly IgM
MemoryStrongWeak
InfantsRespond wellPoor responses to TI-2 antigens

Linked recognition (hapten–carrier effect): a B cell specific for a hapten gets help from T cells specific for the carrier, because it internalises the conjugate and presents carrier peptides. This is exactly how conjugate vaccines turn a polysaccharide into a T-dependent antigen.

Primary vs secondary response: the primary response has a lag, peaks lower and is dominated by IgM; the secondary response is faster, larger, longer-lasting, mainly IgG (or IgA/IgE) and of higher affinity.


Complement

flowchart TB
  CL["Classical:
C1q binds antigen-bound IgM/IgG
C1r, C1s"] --> C42["C4b2a
(classical/lectin C3 convertase)"] LE["Lectin:
MBL or ficolins bind microbial sugars
MASP-1, MASP-2"] --> C42 AL["Alternative:
spontaneous C3 'tick-over'
factor B, factor D, properdin"] --> C3B["C3bBb
(alternative C3 convertase)"] C42 --> C3["C3 → C3a + C3b"] C3B --> C3 C3 --> C5["C5 convertases
C4b2a3b / C3bBb3b"] C3 --> OP["C3b, iC3b: opsonisation
C3d: B-cell co-receptor"] C5 --> C5A["C5a: chemotaxis, anaphylatoxin"] C5 --> MAC["C5b + C6 + C7 + C8 + many C9
= Membrane attack complex"]
  • C3 is the hub of all three pathways. Its internal thioester lets C3b attach covalently to nearby surfaces.
  • Older and most exam texts call the large C2 fragment C2a, giving C4b2a; some newer texts rename it C2b. Learn the structure, not the letter.
  • Functions: lysis (MAC), opsonisation (C3b, iC3b), inflammation (C3a, C5a anaphylatoxins; C5a is strongly chemotactic), and clearance of immune complexes.
  • Regulators protect host cells: C1 inhibitor (deficiency: hereditary angioedema), DAF (CD55) and MCP (CD46) accelerate convertase decay or act as cofactors; factor H and factor I inactivate C3b; CD59 blocks MAC assembly. Loss of GPI-anchored DAF and CD59 from red cells causes paroxysmal nocturnal haemoglobinuria.
DeficiencyTypical consequence
Early classical (C1q, C2, C4)Immune-complex disease, SLE-like
C3Severe recurrent pyogenic infections
Terminal (C5–C9)Recurrent Neisseria infections
C1 inhibitorHereditary angioedema

Hypersensitivity (Gell and Coombs)

TypeMediatorMechanismTimingClassic examples
I ImmediateIgEAllergen crosslinks IgE on mast cells → histamine, leukotrienes, prostaglandinsMinutesAnaphylaxis, hay fever, allergic asthma, urticaria
II CytotoxicIgG/IgM against cell-surface or matrix antigensComplement lysis, opsonisation, ADCC; or receptor stimulation/blockadeHoursTransfusion reactions, haemolytic disease of the newborn, autoimmune haemolytic anaemia, Goodpasture syndrome; Graves’ disease and myasthenia gravis (receptor antibodies)
III Immune complexSoluble antigen–antibody complexesDeposition in vessels, kidney, joints → complement, neutrophilsHoursSerum sickness, Arthus reaction, SLE
IV Delayed-typeT cells (Th1, CD8)Cytokines activate macrophages; direct killing24–72 hTuberculin skin test, contact dermatitis (nickel), granulomas

Types I–III are antibody-mediated and can be transferred with serum; type IV is cell-mediated and transferred with T cells. Rh incompatibility in pregnancy (type II) is covered in Blood and Cardiovascular System.


Tolerance and Autoimmunity

Central tolerance

  • T cells (thymus): double-negative → double-positive (CD4⁺CD8⁺) thymocytes. Positive selection in the cortex keeps cells whose TCR binds self-MHC weakly (MHC restriction; CD4 vs CD8 lineage choice). Negative selection in the medulla deletes cells that bind self-peptide–MHC strongly. AIRE lets medullary epithelial cells express tissue-restricted self-antigens (insulin, for example).
  • B cells (bone marrow): strongly self-reactive immature B cells undergo receptor editing (new light-chain rearrangement), clonal deletion or anergy.

Peripheral tolerance: anergy (signal 1 without 2), regulatory T cells (CD4⁺CD25⁺FoxP3⁺), activation-induced cell death via Fas, and antigens hidden from lymphocytes (immunologically privileged sites).

When tolerance fails

  • Genes: AIRE loss → multi-organ autoimmunity (APECED); FOXP3 loss → IPEX (scurfy in mice); Fas/FasL defects → lymphoproliferation; HLA associations (HLA-B27 with ankylosing spondylitis; HLA-DR3/DR4 with type 1 diabetes).
  • Triggers: molecular mimicry (antibodies against a streptococcal M protein cross-react with heart tissue in rheumatic fever), release of sequestered antigens after injury, bystander activation during inflammation.
Organ-specificSystemic
Type 1 diabetes, Hashimoto thyroiditis, Graves’ disease, myasthenia gravis, multiple sclerosisSLE, rheumatoid arthritis

Immunodeficiency

Primary immunodeficiencies are inherited; secondary ones are acquired. Read each primary defect from the pathway it breaks:

DefectMissing stepResult
RAG1/RAG2 deficiencyV(D)J recombinationNo T or B cells (NK present): SCID
X-linked SCID (common γ chain, IL2RG)Signalling by IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 receptorsNo T or NK cells; B cells present but without T help
ADA deficiencyPurine salvage; toxic deoxyadenosine metabolitesLymphocyte death: SCID
X-linked agammaglobulinaemia (BTK)Pre-BCR signallingB-cell arrest at pre-B; all Ig classes very low
X-linked hyper-IgM (CD40L)T-cell help for CSRHigh/normal IgM, little IgG, IgA, IgE
AID deficiencySHM and CSRHyper-IgM (autosomal)
DiGeorge (22q11.2 deletion)Thymus (and parathyroid) developmentFew T cells; hypocalcaemia
MHC class II deficiency (“bare lymphocyte”)Class II expressionFew CD4 T cells
TAP deficiencyClass I loadingFew CD8 T cells
Chronic granulomatous diseasePhagocyte NADPH oxidasePhagocytes ingest but cannot kill; granulomas
Leukocyte adhesion deficiency type 1 (CD18, β2 integrin)Firm adhesion and extravasationNeutrophilia in blood, few in tissues

Secondary causes: malnutrition, immunosuppressive and cytotoxic drugs, ageing, loss of the spleen, and infections that deplete immune cells (HIV depletes CD4 T cells). For disease details stay with Kuby and the host–pathogen topic of this chapter.


Vaccines as an Immunological Concept

Active immunisation stimulates the recipient’s own lymphocytes and gives memory. Passive immunisation transfers ready-made antibody (maternal IgG across the placenta, IgA in milk, antibody preparations): immediate but temporary, with no memory.

Vaccine typeWhat the immune system meetsResponse and memory
Live attenuatedA weakened replicating organism; antigen made inside host cellsAntibody and CD8 T cells via class I; long-lived memory, often few doses. Not for the immunocompromised
Inactivated (killed)Non-replicating whole organismMainly antibody and CD4 help; boosters and adjuvant usually needed
Subunit / recombinant proteinPurified protein antigensAntibody and CD4 help; needs adjuvant; little CD8
ToxoidInactivated toxinNeutralising antibody against the toxin
PolysaccharideCapsular sugar aloneT-independent: IgM, little switching, weak memory, poor in infants
ConjugatePolysaccharide coupled to a carrier proteinT-dependent via linked recognition: IgG, affinity maturation, memory, works in infants
Nucleic acid (mRNA, DNA) and viral vectorAntigen made inside host cells from delivered genetic instructionsAntibody and CD8 T cells (class I presentation), plus CD4 help

The common thread: where the antigen is made decides the MHC pathway. Antigen synthesised inside host cells reaches class I and primes CD8 T cells; antigen given as protein is mainly exogenous and favours class II, CD4 help and antibody (except through cross-presentation).


Memory Tricks

Don’t Confuse

ThisvsThat
Antigen: binds antibody/TCRvsImmunogen: induces a response
B-cell epitope: surface, often conformationalvsT-cell epitope: linear peptide on MHC
Papain: 2 Fab + FcvsPepsin: F(ab′)₂
Junctional diversity: TdT, P/N-nucleotides; before antigenvsSomatic hypermutation: AID; after antigen, in germinal centres
Class switching: DNA deletion, new C region, same VDJvsIgM + IgD co-expression: alternative splicing, no DNA change
Class I: closed groove, 8–10-mers, all nucleated cells, CD8vsClass II: open groove, longer peptides, APCs, CD4
TAP: carries peptides into the ER (class I)vsInvariant chain / HLA-DM: protect and load class II
Anergy: signal 1 without CD28–B7vsDeletion: strong self-recognition in thymus
CTLA-4: inhibitory, high B7 affinityvsCD28: activating B7 receptor
Classical/lectin C3 convertase: C4b2avsAlternative C3 convertase: C3bBb (stabilised by properdin)
Type II: antibody against cell-bound antigenvsType III: soluble immune complexes deposited
Polysaccharide vaccine: TI, IgM, weak memoryvsConjugate vaccine: TD, IgG, memory

Common Mistakes


Practice

All questions below are original practice questions written in CSIR NET style. They are not previous-year questions.

Level 1: Foundation

  1. Which TLR recognises bacterial flagellin?
  2. Which enzyme adds non-templated N-nucleotides at V(D)J junctions?
  3. Which molecule exchanges CLIP for antigenic peptide in the MHC class II pathway?
Answers
  1. TLR5.
  2. Terminal deoxynucleotidyl transferase (TdT).
  3. HLA-DM (H-2M in mouse).

Level 2: Part B Style

Q1 (practice). A myeloma cell line used for hybridoma production lacks HGPRT. In HAT medium after fusion with spleen cells, which cells grow out?

  • (a) Unfused myeloma cells only
  • (b) Unfused spleen B cells only
  • (c) Myeloma–spleen cell hybrids only
  • (d) Myeloma–myeloma fusions and hybrids
Answer and explanation

(c). Aminopterin blocks de novo nucleotide synthesis. Myeloma cells (and myeloma–myeloma fusions) lack HGPRT and cannot use the salvage pathway, so they die. Unfused B cells have HGPRT but a finite lifespan. Only hybrids combine HGPRT (from the B cell) with immortality (from the myeloma).

Q2 (practice). Mice lacking β₂-microglobulin would be expected to show:

  • (a) Absence of B cells
  • (b) Very few mature CD8 T cells
  • (c) Very few mature CD4 T cells
  • (d) No complement activity
Answer and explanation

(b). Without β₂m, class I molecules are unstable and barely reach the cell surface, so thymocytes cannot be positively selected into the CD8 lineage. CD4 T cells (class II) and B cells develop.

Q3 (practice). A boy has recurrent infections, normal-to-high serum IgM, and very low IgG, IgA and IgE. His B cells switch class normally when stimulated in culture with anti-CD40 antibody and IL-4. The most likely defect is in:

  • (a) AID
  • (b) CD40 ligand on T cells
  • (c) BTK
  • (d) RAG1
Answer and explanation

(b). Hyper-IgM with B cells that can switch when CD40 is engaged artificially means the B cells are intrinsically normal; the missing signal is T-cell CD40L (X-linked, fitting a boy). An AID defect would block switching even in culture. BTK and RAG defects remove B cells.

Q4 (practice). A newborn has a maternal anti-toxin IgG titre of 1:1,280. Protection is assumed to require a titre of at least 1:80, and IgG is assumed to decay with a half-life of 21 days with no new synthesis. For roughly how long is the infant protected?

  • (a) 42 days
  • (b) 63 days
  • (c) 84 days
  • (d) 105 days
Answer and explanation

(c). 1,280 → 640 → 320 → 160 → 80 is 4 half-lives: \(t = 21 \times \log_2(1280/80) = 21 \times 4 = 84\) days. This is passive immunity: no memory is formed, which is why active immunisation is still needed.

Level 3: Part C Style

Q1 (practice). A hypothetical mammal has, in its germline, 40 functional V\(_H\), 25 D and 6 J\(_H\) segments; 35 V\(_\kappa\) and 5 J\(_\kappa\); 30 V\(_\lambda\) and 4 J\(_\lambda\).

(i) How many different heavy chains and light chains can combinatorial joining alone produce? (ii) How many antibody specificities can result from combinatorial joining and H–L pairing? (iii) Which statement is correct?

  • (a) The real repertoire is smaller than (ii) because of allelic exclusion.
  • (b) The real repertoire is much larger than (ii) because of junctional diversity and somatic hypermutation.
  • (c) Somatic hypermutation adds diversity before antigen exposure.
  • (d) Class switching increases the number of specificities.
Answer and worked solution
  1. Heavy chains: \(40 \times 25 \times 6 = \) 6,000. Light chains: κ \(35 \times 5 = 175\); λ \(30 \times 4 = 120\); total 295.
  2. Pairing: \(6000 \times 295 = \) 1,770,000 (about \(1.8 \times 10^6\)).
  3. (b). Imprecise joining, P- and N-nucleotides (mostly in CDR3) and antigen-driven SHM multiply the combinatorial number many-fold. Allelic exclusion makes each B cell express one specificity; it does not shrink the population repertoire (a). SHM is antigen-dependent (c). Class switching changes the constant region, not specificity (d).

Q2 (practice). Complement function is tested in four patients’ sera. CH50 measures lysis by the classical pathway (and terminal components); AH50 measures lysis by the alternative pathway (and terminal components). Results as percent of normal:

PatientCH50AH50Clinical note
P< 595Rash, arthritis, anti-nuclear antibodies
Q< 5< 5Recurrent Neisseria infections
R100< 5Recurrent infections
S< 5< 5Severe recurrent pyogenic infections from infancy

Which assignment is most consistent?

  • (a) P: C2; Q: C7; R: factor B; S: C3
  • (b) P: C3; Q: C2; R: C7; S: factor D
  • (c) P: factor B; Q: C4; R: C2; S: C9
  • (d) P: C7; Q: C3; R: C1q; S: factor B
Answer and explanation

(a).

  • P: only the classical pathway is lost, so the defect is in C1, C4 or C2. SLE-like disease fits an early classical deficiency (poor immune-complex clearance). C2 fits.
  • Q: both assays fail, so the defect is in a shared component (C3 or C5–C9). Recurrent Neisseria points to a terminal component such as C7.
  • R: only the alternative pathway is lost: factor B, factor D or properdin.
  • S: both fail with severe pyogenic infections from infancy: C3, the hub of opsonisation.

Q3 (practice). CD8 T cells are taken from mouse strain A (H-2ᵏ) immunised with cells expressing protein X in their cytosol. They are tested for killing of target cells in a chromium-release assay:

Target cellsMHCExpress protein X?Specific lysis
T1H-2ᵏYes62%
T2H-2ᵏNo3%
T3H-2ᵇYes4%
T4H-2ᵏ, TAP-deficientYes6%
T5H-2ᵏ, TAP-deficient, pulsed with a synthetic X peptideNo (peptide only)58%

Which statements are correct?

  • A. Recognition requires both protein X and self MHC (H-2ᵏ).
  • B. Protein X must be processed and transported into the ER to be seen on intact cells.
  • C. TAP is required for the CTL to bind peptide–MHC on the target surface.
  • D. The epitope is presented on MHC class II.

Options: (a) A and B only (b) A, B and C (c) B and D only (d) A and D only

Answer and explanation

(a).

  • A is correct: T1 vs T2 shows antigen specificity; T1 vs T3 shows MHC restriction (same antigen on a different MHC is not recognised).
  • B is correct: T4 makes protein X but, without TAP, cytosolic peptides do not reach class I.
  • C is wrong: T5 shows that once peptide is loaded from outside onto surface class I, TAP-deficient cells are killed. TAP is needed for loading, not for recognition.
  • D is wrong: CD8 T cells, cytosolic antigen and TAP dependence all mark class I.

Quick Revision Table

ItemFact
PRRsTLRs, NLRs (NOD1/2, NLRP3), RLRs (RIG-I, MDA5), cGAS–STING, C-type lectins
TLR ligands4 LPS; 2 (+1/6) lipopeptides; 5 flagellin; 3 dsRNA; 7/8 ssRNA; 9 CpG DNA
TLR adaptorsMyD88 all but TLR3; TRIF for TLR3 and TLR4
InflammasomeNLRP3 + ASC + caspase-1 → IL-1β, IL-18, gasdermin D (pyroptosis)
ExtravasationSelectin rolling → chemokine → integrin (LFA-1–ICAM-1) → diapedesis
HaptenAntigenic, not immunogenic without carrier
Ig structure2H + 2L; κ or λ; CDR1–3, CDR3 most variable; papain 2 Fab + Fc; pepsin F(ab′)₂
Ig classesIgG placenta; IgM pentamer, first, complement; IgA dimer in secretions; IgE mast cells; IgD naive B
V(D)JRAG1/2, RSS 12/23 rule; Artemis (P), TdT (N), NHEJ ligase IV
AIDSHM (affinity maturation) and CSR (switch regions)
HybridomaHGPRT⁻ myeloma + B cell; HAT selects hybrids; limiting-dilution cloning
MHC Iα + β₂m; 8–10-mers; all nucleated cells; CD8; proteasome → TAP → tapasin
MHC IIα + β; longer peptides; APCs; CD4; Ii → CLIP → HLA-DM
Cross-presentationcDC1: exogenous antigen on class I → CD8 priming
T-cell signals1 TCR–pMHC; 2 CD28–B7; 3 cytokines; 1 without 2 = anergy
Th subsetsTh1 T-bet IFN-γ; Th2 GATA3 IL-4; Th17 RORγt IL-17; Tfh Bcl-6 IL-21; Treg FoxP3
TD vs TITD: CD40L, GC, switch, memory. TI: IgM, weak memory, poor in infants
ComplementClassical C1q; lectin MBL/MASP; alternative C3 tick-over, B, D, properdin; MAC C5b–9
RegulatorsC1-INH, DAF/CD55, MCP/CD46, factor H, factor I, CD59
HypersensitivityI IgE; II antibody on cells; III immune complexes; IV T cells, 24–72 h
ToleranceThymic +/− selection, AIRE; receptor editing; Tregs (FoxP3); anergy; Fas
Primary IDRAG/IL2RG/ADA SCID; BTK XLA; CD40L hyper-IgM; DiGeorge; CGD; LAD-1
VaccinesLive and nucleic-acid: CD8 + antibody; killed/subunit/toxoid: antibody; conjugate: TD memory

Key Takeaways

What’s Next

Advertisement
Advertisement